At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 27 enrolled
Drug / intervention
piclozotan +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Placebo-Controlled, Preliminary Study of the Efficacy, Safety, and Tolerability of Intravenous SUN N4057 in Patients With Motor Complications Associated With Parkinson's Disease
In Brief
A Phase 2 clinical trial evaluating piclozotan and 0.9% sodium chloride (normal saline) for Parkinson's Disease. Completed, enrolled 27 participants across 7 sites in 3 countries.
Detailed Summary
The purpose of this study is to obtain preliminary information on the effect of piclozotan on motor complications associated with Parkinson's Disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
CountriesGuatemala, Romania, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2007
First PostedFeb 2008
Primary CompletionJul 2008
TodayJul 2026
First PostedFeb 26, 2008
Enrollment StartJul 13, 2007
Primary CompletionJul 17, 2008
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 18.3 years ago
Interventions
piclozotandrug
piclozotan, intravenous (IV) infusion
0.9% sodium chloride (normal saline)drug
0.9% sodium chloride (normal saline) intravenous (IV) infusion